Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of “Buy” by Analysts

Omnicell, Inc. (NASDAQ:OMCL) has received a consensus rating of “Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $59.8571.

OMCL has been the subject of a number of research reports. Zacks Research upgraded Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Benchmark reiterated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Finally, Craig Hallum reiterated a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Wednesday, April 29th.

Insider Transactions at Omnicell

In related news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 7,405 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the transaction, the executive vice president owned 96,717 shares of the company’s stock, valued at approximately $3,355,112.73. The trade was a 7.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 15,520 shares of company stock valued at $607,610. 2.92% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Dana Investment Advisors Inc. acquired a new position in Omnicell during the fourth quarter valued at approximately $3,445,000. Assenagon Asset Management S.A. boosted its position in Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock valued at $11,698,000 after purchasing an additional 117,556 shares during the last quarter. Peregrine Capital Management LLC acquired a new position in Omnicell during the fourth quarter valued at approximately $4,804,000. Dynamic Technology Lab Private Ltd boosted its position in Omnicell by 345.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock valued at $971,000 after purchasing an additional 24,738 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Omnicell by 71.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock valued at $6,343,000 after purchasing an additional 58,193 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Down 1.4%

Shares of Omnicell stock opened at $43.00 on Friday. Omnicell has a 1 year low of $26.84 and a 1 year high of $55.00. The business has a 50-day moving average of $39.86 and a two-hundred day moving average of $41.32. The company has a market capitalization of $1.96 billion, a P/E ratio of 97.73, a price-to-earnings-growth ratio of 1.11 and a beta of 0.97. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.Omnicell’s quarterly revenue was up 14.9% on a year-over-year basis. During the same period last year, the company earned $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, equities analysts predict that Omnicell will post 1.31 EPS for the current year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.